Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Armen G Aprikian"'
Publikováno v:
Urology Annals, Vol 6, Iss 2, Pp 176-178 (2014)
Renal angiomyolipoma with inferior vena caval venous extension is rare with only 40 cases reported in the literature. We report a case of a 35-year-old lady with angiomyolipoma with inferior vena caval thrombus that was managed surgically with roboti
Externí odkaz:
https://doaj.org/article/a1dcbc06055f4d8e963f849758c5db6e
Autor:
Salaheddin M Mahmud, Eduardo L Franco, Donna Turner, Robert W Platt, Patricia Beck, David Skarsgard, Jon Tonita, Colin Sharpe, Armen G Aprikian
Publikováno v:
PLoS ONE, Vol 6, Iss 1, p e16412 (2011)
BACKGROUND: Despite strong laboratory evidence that non-steroidal anti-inflammatory drugs (NSAIDs) could prevent prostate cancer, epidemiological studies have so far reported conflicting results. Most studies were limited by lack of information on do
Externí odkaz:
https://doaj.org/article/ce7945cfd40842d093986dd99cb90a98
Autor:
Michel D. Wissing, Ana O’Flaherty, Alice Dragomir, Simon Tanguay, Wassim Kassouf, Armen G. Aprikian
Publikováno v:
BMC Urology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Studies have suggested a positive association between bladder cancer (BC) outcome and comedication use, including nonsteroidal anti-inflammatory drugs (NSAID), metformin, and prednisone use. To validate these associations, we eval
Externí odkaz:
https://doaj.org/article/587dd4100c534cd0a058880266c10eda
Autor:
Saro Aprikian, Murilo Luz, Fadi Brimo, Eleonora Scarlata, Lucie Hamel, Fabio L. Cury, Simon Tanguay, Armen G. Aprikian, Wassim Kassouf, Simone Chevalier
Publikováno v:
BMC Urology, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background To define a new coefficient to be used in the formula (Volume = L x H x W x Coefficient) that better estimates prostate volume using dimensions of fresh prostates from patients who had transrectal ultrasound (TRUS) imaging prior t
Externí odkaz:
https://doaj.org/article/fbc8a6788ce94c449c59c5b7acefbb6a
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:163-171
Background: Controversy exists regarding the risk of cardiovascular disease (CVD) associated with androgen deprivation therapy (ADT) in patients with prostate cancer. We sought to evaluate the association between gonadotropin-releasing hormone (GnRH)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8179cefb793a78411f9b1133d73c56c
https://doi.org/10.6004/jnccn.2022.7083
https://doi.org/10.6004/jnccn.2022.7083
Publikováno v:
Current Oncology; Volume 29; Issue 11; Pages: 8626-8637
Background: The introduction of novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) was an important milestone given their survival benefits, tolerability,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7937c36b8856961634f2b0076acb516c
https://doi.org/10.3390/curroncol29110680
https://doi.org/10.3390/curroncol29110680
Autor:
Walead Ebrahimizadeh, Karl-Philippe Guérard, Shaghayegh Rouzbeh, Eleonora Scarlata, Fadi Brimo, Palak G. Patel, Tamara Jamaspishvili, Lucie Hamel, Armen G. Aprikian, Anna Y. Lee, David M. Berman, John M. S. Bartlett, Simone Chevalier, Jacques Lapointe
Publikováno v:
British Journal of Cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0568e14e7646d2bce1d3d62e59885af2
https://doi.org/10.1038/s41416-023-02236-8
https://doi.org/10.1038/s41416-023-02236-8
Publikováno v:
Current Oncology. 29:3393-3424
Background: Health economic evaluations are needed to assess the impact on the healthcare system of emerging treatment patterns for advanced prostate cancer. The objective of this study is to review the scientific literature identifying cost-effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463687e3e9913085906dbe844751df5a
https://doi.org/10.3390/curroncol29050275
https://doi.org/10.3390/curroncol29050275
Publikováno v:
Journal of Clinical Oncology. 40:238-238
238 Background: Androgen deprivation therapy (ADT) is a staple of advanced prostate cancer (PCa) treatment, however several side-effects are associated with its long-term use. Notably, loss of bone mineral density (BMD) is accelerated which increases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9a958a0fcc2533a579426d8244b2d45
https://doi.org/10.1200/jco.2022.40.28_suppl.238
https://doi.org/10.1200/jco.2022.40.28_suppl.238
Autor:
Yogesh M. Bramhecha, Karl-Philippe Guérard, Étienne Audet-Walsh, Shaghayegh Rouzbeh, Ola Kassem, Erwan Pernet, Eleonora Scarlata, Lucie Hamel, Fadi Brimo, Maziar Divangahi, Armen G. Aprikian, Simone Chevalier, Vincent Giguère, Jacques Lapointe
Publikováno v:
Oncogene. 41(20)
Prostate cancer (PCa) metastases are highly enriched with genomic alterations including a gain at the 16p13.3 locus, recently shown to be associated with disease progression and poor clinical outcome. ECI1, residing at the 16p13.3 gain region, encode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13df9f864a50b8b255b1bcb3f4656774
https://pubmed.ncbi.nlm.nih.gov/35411033
https://pubmed.ncbi.nlm.nih.gov/35411033